Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York NY, USA; 2 Department of Psychiatry and Molecular Med- icine, Zucker School of Medicine at Hofstra/Northwell, Hempstead NY, USA; 3 Center for Psychiatric Neuroscience, Feinstein Institute for Medical Re- search, Manhasset NY, USA; 4 Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin Germany; 5 Center for Innova- tion in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton UK; 6 Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton UK; 7 Solent NHS Trust, Southampton UK; 8 Hassenfeld Children's Hospital at NYU Langone, New York University Child Study Center, New York NY, USA; 9 Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham UK; 10Neurosciences Department, University of Padua, Padua Italy; 11Depart- ment of Mental Health, ASL Salerno, Salerno Italy; 12Integrated Psychiatry Winterthur, Winterthur Switzerland; 13Mind-Brain Group, Institute for Culture and Society, University of Navarra, Pamplona Spain; 14Psychiatry Department, Oxford University, Oxford UK; 15Department of Health Sciences, Univer- sity of Milan, Milan Italy; 16Department of Psychiatry, Federico II University, Naples Italy; 17Early Psychosis: Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London UK; 18Department of Clinical and Health Psychology, Catholic University, Montevideo Uruguay; 19OASIS Service, South London and Maudsley NHS Foundation Trust, London UK; 20Department of Brain and Behavioral Sciences, University of Pavia, Pavia Italy; 21Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London UK; 22Department of Psychiatry, University of Toronto, Toronto ON, Canada; 23Centre for Addiction and Mental Health (CAMH), Toronto ON, Canada
Список исп. литературыСкрыть список 1. Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602. 2. Caspi A, Houts RM, Ambler A et al. Longitudinal assessment of mental health disorders and comorbidities across 4 decades among participants in the Dunedin birth cohort study. JAMA Netw Open 2020;3:e203221. 3. Wang PS, Berglund P, Olfson M et al. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:603-13. 4. GBD 2017 Child and Adolescent Health Collaborators . Diseases, injuries, and risk factors in child and adolescent health, 1990 to 2017: findings from the global burden of diseases, injuries, and risk factors 2017 Study. JAMA Pediatr 2019;173:e190337. 5. Cortese S, Adamo N, Del Giovane C et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018;5:727-38. 6. Pillay J, Boylan K, Carrey N et al. First- and second-generation antipsychotics in children and young adults: systematic review update. Rockville: US Agency for Healthcare Research and Quality, 2017. 7. Cipriani A, Zhou X, Del Giovane C et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 2016;388:881-90. 8. Pagsberg AK, Tarp S, Glintborg D et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry 2017;56:191-202. 9. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018;391:1357-66. 10. Zhou X, Teng T, Zhang Y et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry 2020;7:581-601. 11. Dobson E, Bloch M, Strawn J. Efficacy and tolerability of pharmacotherapy for anxiety disorders. J Clin Psychiatry 2019;80:17r12064. 12. James AC, Reardon T, Soler A et al. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2020;11:CD013162. 13. Huhn M, Tardy M, Spineli LM et al. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry 2014;71:706-15. 14. Solmi M, Fornaro M, Ostinelli EG et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry 2020;19:214-32. 15. Reed GM, First MB, Kogan CS et al. Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry 2019;18:3-19. 16. Correll CU, Rubio JM, Inczedy-Farkas G et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 2017;74:675-84. 17. Shea BJ, Grimshaw JM, Wells GA et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:10. 18. Borenstein M, Hedges L, Higgins JPT et al. Comprehensive meta-analysis (Version 2.2.027). www.meta-analysis.com/. 19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. 20. Catalá-López F, Hutton B, Núñez-Beltrán A et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS One 2017;12:e0180355. 21. Luan R, Mu Z, Yue F et al. Efficacy and tolerability of different interventions in children and adolescents with attention deficit hyperactivity disorder. Front Psychiatry 2017;8:229. 22. Otasowie J, Castells X, Ehimare UP et al. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2014;19:CD006997. 23. Punja S, Shamseer L, Hartling L et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents (Review). Cochrane Database Syst Rev 2016;2:CD009996. 24. Sun C-K, Tseng P-T, Wu C-K et al. Therapeutic effects of methylphenidate for attention-deficit/hyperactivity disorder in children with borderline intellectual functioning or intellectual disability: a systematic review and meta-analysis. Sci Rep 2019;9:15908. 25. Battagliese G, Caccetta M, Ines O et al. Behaviour research and therapy cognitive-behavioral therapy for externalizing disorders: a meta-analysis of treatment effectiveness. Behav Res Ther 2015;75:60-71. 26. Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol 2002;22:468-73. 27. Van Doren J, Arns M, Heinrich H et al. Sustained effects of neurofeedback in ADHD: a systematic review and meta-analysis. Eur Child Adolesc Psychiatry 2019;28:293-305. 28. Cortese S, Ferrin M, Brandeis D et al. Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry 2015;54:164-74. 29. Daley D, Van Der Oord S, Ferrin M et al. Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains. J Am Acad Child Adolesc Psychiatry 2014;53:835-47. 30. Bikic A, Reichow B, McCauley SA et al. Meta-analysis of organizational skills interventions for children and adolescents with attention-deficit/hyperactivity disorder. Clin Psychol Rev 2017;52:108-23. 31. Mulqueen JM, Bartley CA, Bloch MH. Meta-analysis: parental interventions for preschool ADHD. J Atten Disord 2015;19:118-24. 32. Cortese S, Ferrin M, Brandeis D et al. Neurofeedback for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry 2016;55:444-55. 33. Bussalb A, Congedo M, Barthélemy Q et al. Clinical and experimental factors influencing the efficacy of neurofeedback in ADHD: a meta-analysis. Front Psychiatry 2019;10:35. 34. Stuhec M, Munda B, Svab V et al. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. J Affect Disord 2015;178:149-59. 35. Faraone SV, Biederman J. Efficacy of Adderall® for attention-deficit/hyperactivity disorder: a meta-analysis. J Atten Disord 2002;6:69-75. 36. Schachter HM, Pham B, King J et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 2001;165:1475-88. 37. Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry 2014;53:174-87. 38. Coghill DR, Seth S, Pedroso S et al. Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. Biol Psychiatry 2014;76:603-15. 39. Storebø OJ, Ramstad E, Krogh HB et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev 2015;11:CD009885. 40. Bangs ME, Wietecha LA, Wang S et al. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. J Child Adolesc Psychopharmacol 2014;24:426-34 41. Hirota T, Schwartz S, Correll C. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry 2014;53:153-73. 42. Storebø OJ, Andersen ME, Skoog M et al. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev 2019;6:CD008223. 43. Fallah MS, Shaikh MR, Neupane B et al. Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. J Child Adolesc Psychopharmacol 2019;29:168-80. 44. Maneeton N, Maneeton B, Putthisri S et al. Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Neuropsychiatr Dis Treat 2018;14:3063-72. 45. Yu Q, Li E, Li L et al. Efficacy of interventions based on applied behavior analysis for autism spectrum disorder: a meta-analysis. Psychiatry Investig 2020;17:432-43. 46. Oono IP, Honey EJ, McConachie H. Parent-mediated early intervention for young children with autism spectrum disorders (ASD). BJPsych Adv 2016;22:146. 47. Parsons L, Cordier R, Munro N et al. A systematic review of pragmatic language interventions for children with autism spectrum disorder. PLoS One 2017;12:e0172242. 48. Kreslins A, Robertson AE, Melville C. The effectiveness of psychosocial interventions for anxiety in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Child Adolesc Psychiatry Ment Health 2015;9:22. 49. Tarver J, Palmer M, Webb S et al. Child and parent outcomes following parent interventions for child emotional and behavioral problems in autism spectrum disorders: a systematic review and meta-analysis. Autism 2019;23:1630-44. 50. Soares EE, Bausback K, Beard CL et al. Social skills training for autism spectrum disorder: a meta-analysis of in-person and technological interventions. J Technol Behav Sci (in press). 51. Postorino V, Sharp WG, McCracken CE et al. A systematic review and meta-analysis of parent training for disruptive behavior in children with autism spectrum disorder. Clin Child Fam Psychol Rev 2017;20:391-402. 52. Maneeton N, Maneeton B, Putthisri S et al. Risperidone for children and adolescents with autism spectrum disorder: a systematic review. Neuropsychiatr Dis Treat 2018;14:1811-20. 53. Zhou MS, Nasir M, Farhat LC et al. Meta-analysis: pharmacologic treatment of restricted and repetitive behaviors in autism spectrum disorders. J Am Acad Child Adolesc Psychiatry 2020;60:35-45. 54. Murza KA, Schwartz JB, Hahs-Vaughn DL et al. Joint attention interventions for children with autism spectrum disorder: a systematic review and meta-analysis. Int J Lang Commun Disord 2016;51:236-51. 55. Sturman N, Deckx L, van Driel ML. Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database Syst Rev 2017;11:CD011144. 56. Fletcher-Watson S, Mcconnell F, Manola E et al. Interventions based on the Theory of Mind cognitive model for autism spectrum disorder (ASD) (Review). Cochrane Database Syst Rev Interv 2014;3:CD008785 57. Cohen D, Raffin M, Canitano R et al. Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: a Bayesian meta-analysis of efficacy and secondary effects. Res Autism Spectr Disord 2013;7:167-75. 58. Hirota T, Veenstra-Vanderweele J, Hollander E et al. Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis. J Autism Dev Disord 2014;44:948-57. 59. D'Alò GL, De Crescenzo F, Amato L et al. Acceptability, equity, and feasibility of using antipsychotics in children and adolescents with autism spectrum disorder: a systematic review. BMC Psychiatry 2020;20:561. 60. Ospina MB, Seida JK, Clark B et al. Behavioural and developmental interventions for autism spectrum disorder: a clinical systematic review. PLoS One 2008;3:e3755. 61. Reichow B, Steiner AM, Volkmar F et al. Social skills groups for people aged 6 to 21 with autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012;7:CD008511. 62. Tachibana Y, Miyazaki C, Ota E et al. A systematic review and meta-analysis of comprehensive interventions for pre-school children with autism spectrum disorder (ASD). PLoS One 2017;12:e0186502. 63. Nevill RE, Lecavalier L, Stratis EA. Meta-analysis of parent-mediated interventions for young children with autism spectrum disorder. Autism 2018;22:84-98. 64. Spielmans GI, Gerwig K. The efficacy of antidepressants on overall well-being and self-reported depression symptom severity in youth: a meta-analysis. Psychother Psychosom 2014;83:158-64. 65. Kato M, Hori H, Inoue T et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry 2020;26:118-33. 66. Whittington CJ, Kendall T, Fonagy P et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5. 67. Watanabe N, Hunot V, Omori IM et al. Psychotherapy for depression among children and adolescents: a systematic review. Acta Psychiatr Scand 2007;116:84-95. 68. Cox GR, Callahan P, Churchill R et al. Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents. Cochrane Database Syst Rev 2014;11:CD008324. 69. Dubicka B, Elvins R, Roberts C et al. Combined treatment with cognitive-behavioural therapy in adolescent depression: meta-analysis. Br J Psychiatry 2010;197:433-40. 70. Klein JB. Cognitive-behavioral therapy for adolescent depression: a meta-analytic investigation of changes in effect-size estimates. J Am Acad Child Adolesc Psychiatry 2007;46:1403-13. 71. Skapinakis P, Caldwell D, Hollingworth W et al. A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults. Health Technol Assess 2016;20:1-392. 72. Maneeton N, Maneeton B, Karawekpanyawong N et al. Fluoxetine in acute treatment of children and adolescents with obsessive-compulsive disorder: a systematic review and meta-analysis. Nord J Psychiatry 2020;74:461-9. 73. McGuire JF, Piacentini J, Lewin AB et al. A meta-analysis of cognitive behavior therapy and medication for child obsessive-compulsive disorder: moderators of treatment efficacy, response, and remission. Depress Anxiety 2015;32:580-93. 74. Locher C, Koechlin H, Zion SR et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. JAMA Psychiatry 2017;74:1011-20. 75. Geller D. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 2003;160:1919-28. 76. Uhre CF, Uhre VF, Lønfeldt NN et al. Systematic review and meta-analysis: cognitive-behavioral therapy for obsessive-compulsive disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 2020;59:64-77. 77. Johnco C, McGuire JF, Roper T et al. A meta-analysis of dropout rates from exposure with response prevention and pharmacological treatment for youth with obsessive compulsive disorder. Depress Anxiety 2020;37:407-17. 78. Zhou X, Zhang Y, Furukawa TA et al. Different types and acceptability of psychotherapies for acute anxiety disorders in children and adolescents: a network meta-analysis. JAMA Psychiatry 2019;76:41-50. 79. Wang Z, Whiteside SPH, Sim L et al. Comparative effectiveness and safety of cognitive behavioral therapy and pharmacotherapy for childhood anxiety disorders: a systematic review and meta-analysis. JAMA Pediatr 2017;171:1049-56. 80. Zhang H, Zhang Y, Yang L et al. Efficacy and acceptability of psychotherapy for anxious young children a meta-analysis of randomized controlled trials. J Nerv Ment Dis 2017;205:931-41. 81. Sigurvinsdóttir AL, Jensínudóttir KB, Baldvinsdóttir KD et al. Effectiveness of cognitive behavioral therapy (CBT) for child and adolescent anxiety disorders across different CBT modalities and comparisons: a systematic review and meta-analysis. Nord J Psychiatry 2020;74:168-80. 82. James A, James G, Cowdrey FA et al. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2015;11:CD013162. 83. Yang L, Zhou X, Pu J et al. Efficacy and acceptability of psychological interventions for social anxiety disorder in children and adolescents: a meta-analysis of randomized controlled trials. Eur Child Adolesc Psychiatry 2019;28:79-89. 84. Kreuze LJ, Pijnenborg GHM, de Jonge YB et al. Cognitive-behavior therapy for children and adolescents with anxiety disorders: a meta-analysis of secondary outcomes. J Anxiety Disord 2018;60:43-57. 85. Song P, Huang C, Wang Y et al. Comparison of desmopressin, alarm, desmopressin plus alarm, and desmopressin plus anticholinergic agents in the management of paediatric monosymptomatic nocturnal enuresis: a network meta-analysis. BJU Int 2019;123:388-400. 86. Caldwell PHY, Codarini M, Stewart F et al. Alarm interventions for nocturnal enuresis in children. Cochrane Database Syst Rev 2020;5:CD002911. 87. Caldwell PHY, Sureshkumar P, Wong WCF. Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Syst Rev 2016;1:CD002117. 88. Caldwell PHY, Nankivell G, Sureshkumar P. Simple behavioural interventions for nocturnal enuresis in children. Cochrane Database Syst Rev 2013;7:CD003637. 89. Buckley BS, Sanders CD, Spineli L et al. Conservative interventions for treating functional daytime urinary incontinence in children. Cochrane Database Syst Rev 2019;9:CD012367. 90. Deshpande AV, Caldwell PH, Sureshkumar P. Drugs for nocturnal enuresis in children (other than desmopressin and tricyclics). Cochrane Database Syst Rev 2012;12:CD002238. 91. Peng CCH, Yang SSD, Austin PF et al. Systematic review and meta-analysis of alarm versus desmopressin therapy for pediatric monosymptomatic enuresis. Sci Rep 2018;8:16755. 92. Seida JC, Schouten JR, Mousavi SS et al. First- and second- generation antipsychotics for children and young adults: comparative effectiveness. Rockville: US Agency for Healthcare Research and Quality, 2012. 93. Loy J, Merry S, Hetrick S et al. Atypical antipsychotic drugs for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev 2017;8:CD008559. 94. Pringsheim T, Hirsch L, Gardner D et al. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Can J Psychiatry 2015;60:52-61. 95. Ipser J, Stein DJ. Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents. Psychopharmacology 2007;191:127-40. 96. McQuire C, Hassiotis A, Harrison B et al. Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis. BMC Psychiatry 2015;15:303. 97. Zeeck A, Herpertz-Dahlmann B, Friederich HC et al. Psychotherapeutic treatment for anorexia nervosa: a systematic review and network meta-analysis. Front Psychiatry 2018;9:158. 98. Couturier J, Kimber M, Szatmari P. Efficacy of family-based treatment for adolescents with eating disorders: a systematic review and meta-analysis. Int J Eat Disord 2013;46:3-11. 99. Fisher CA, Skocic S, Rutherford KA et al. Family therapy approaches for anorexia nervosa. Cochrane Database Syst Rev 2019;5:CD004780. 100. van den Berg E, Houtzager L, de Vos J et al. Meta-analysis on the efficacy of psychological treatments for anorexia nervosa. Eur Eat Disord Rev 2019;27:331-51. 101. Linardon J, Wade TD, de la Piedad Garcia X et al. The efficacy of cognitive-behavioral therapy for eating disorders: a systematic review and meta-analysis. J Consult Clin Psychol 2017;85:1080-94. 102. Krause M, Zhu Y, Huhn M et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. Eur Neuropsychopharmacol 2018;28:659-74. 103. Arango C, Ng-Mak D, Finn E et al. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. Eur Child Adolesc Psychiatry 2020;29:1195-205. 104. Sarkar S, Grover S. Antipsychotics in children and adolescents with schizophrenia: a systematic review and meta-analysis. Indian J Pharmacol 2013;45:439-46. 105. Kumar A, Datta SS, Wright SD et al. Atypical antipsychotics for psychosis in adolescents. Cochrane Database Syst Rev 2013;10:CD009582. 106. Maneeton B, Putthisri S, Maneeton N et al. Quetiapine monotherapy versus placebo in the treatment of children and adolescents with bipolar depression: a systematic review and meta-analysis. Neuropsychiatr Dis Treat 2017;13:1023. 107. Meduri M, Gregoraci G, Baglivo V et al. A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies. J Affect Disord 2016;191:187-208. 108. Liu HY, Potter MP, Woodworth KY et al. Pharmacologic treatments for pediatric bipolar disorder: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry 2011;50:749-62. 109. Jochim J, Rifkin-Zybutz R, Geddes J et al. Valproate for acute mania. Cochrane Database Syst Rev 2019;10:CD004052. 110. Bloch MH, Panza KE, Landeros-Weisenberger A et al. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009;48:884-93. 111. Yu L, Yan J, Wen F et al. Revisiting the efficacy and tolerability of topiramate for tic disorders: a meta-analysis. J Child Adolesc Psychopharmacol 2020;30:316-25. 112. Hollis C, Pennant M, Cuenca J et al. Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis. Health Technol Assess 2016;20:1-450 113. Zheng W, Li X, XIang Y et al. Aripiprazole for Tourette's syndrome: a systematic review and metaanalysis. Hum Psychopharmacol Clin Exp 2016;31:11-8. 114. Freeman K, Riley A, Duke D et al. Systematic review (and meta-analysis) of behavioral interventions for fecal incontinence with constipation. J Pediatr Psychol 2014;39:887-902. 115. Brazzelli M, Griffiths P, Cody JT et al. Behavioural and cognitive interventions with or without other treatments for the management of faecal incontinence in children. Cochrane Database Syst Rev 2011;12:CD0022400. 116. Miyahara M, Sl H, Pridham L et al. Task-oriented interventions for children with developmental co-ordination disorder. Cochrane Database Syst Rev 2017;7:CD010914. 117. Gillies D, Taylor F, Gray C et al. Psychological therapies for the treatment of post-traumatic stress disorder in children and adolescents (Review). Evid Based Child Health 2013;8:1004-116. 118. Scotto Rosato N, Correll CU, Pappadopulos E et al. Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. Pediatrics 2012;129:e1577-86. 119. Knapp P, Chait A, Pappadopulos E et al. Treatment of maladaptive aggression in youth: CERT guidelines I. Engagement, assessment, and management. Pediatrics 2012;129:e1562-76. 120. Findling RL, Robb A, McNamara NK et al. Lithium in the acute treatment of bipolar i disorder: a double-blind, placebo-controlled study. Pediatrics 2015;136:885-94. 121. Bahji A, Ermacora D, Stephenson C et al. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis. J Affect Disord 2020;269:154-84. 122. DelBello MP, Goldman R, Phillips D et al. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2017;56:1015-25. 123. Detke HC, DelBello MP, Landry J et al. Olanzapine/fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2015;54:217-24. 124. Skarphedinsson G, Hanssen-Bauer K, Kornør H et al. Standard individual cognitive behaviour therapy for paediatric obsessive-compulsive disorder: a systematic review of effect estimates across comparisons. Nord J Psychiatry 2015;69:81-92. 125. Andersson G, Titov N, Dear BF et al. Internet-delivered psychological treatments: from innovation to implementation. World Psychiatry 2019;18:20-8. 126. Linardon J, Cuijpers P, Carlbring P et al. The efficacy of app-supported smartphone interventions for mental health problems: a meta-analysis of randomized controlled trials. World Psychiatry 2019;18:325-36. 127. Cuijpers P. Targets and outcomes of psychotherapies for mental disorders: an overview. World Psychiatry 2019;18:276-85. 128. Cuijpers P, Noma H, Karyotaki E et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry 2020;19:92- 107.